首页 › 基金 › Bellevue Group AG › PCVX
Bellevue Group AG 对 PCVX 的持仓历史
VAXCYTE INC · 医疗保健
Bellevue Group AG 在 Q2 2026 的 13F 申报中披露持有 PCVX(VAXCYTE INC)1,971,935 股,市值约 US$114.6M,约占其申报组合的 2.41%,在其申报持仓中市值排名第 12 位。 Bellevue Group AG 最近 12 个申报季度中有 9 个季度披露了 PCVX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Bellevue Group AG 对 PCVX 的持仓演变
Bellevue Group AG 于 Q3 2023 首次披露 PCVX 持仓:30,500 股(约 US$1.6M)。 该持仓在 Q2 2026 达到峰值 1,971,935 股,市值约 US$114.6M。 在 9 次申报中,Bellevue Group AG 2 次增持、4 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 1,971,935 股、市值约 US$114.6M,环比增持 781,238 股。。 持仓曾出现大幅变动:Q4 2023 减持约 48% (随后一个季度股价上涨 9%)、Q2 2026 增持约 66% (随后一个季度股价下跌 2%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 30.50K | $1.55M | 新进 |
| Q4 2023 | 15.80K | $992.24K | 减持 |
| Q1 2024 | 13.24K | $904.70K | 减持 |
| Q2 2024 | 14.21K | $1.07M | 增持 |
| Q3 2024 | 11.98K | $1.37M | 减持 |
| Q4 2024 | 12.04K | $985.43K | 持有 |
| Q1 2025 | 11.29K | $426.31K | 减持 |
| Q1 2026 | 1.19M | $69.19M | 新进 |
| Q2 2026 | 1.97M | $114.63M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PCVX 与 13F 数据
PCVX(VAXCYTE INC)属于医疗保健行业。我们追踪的基金中还有 35 只申报持有 PCVX,申报仓位最大的包括:Jupiter Topco LLC (US$1.04B), 骏利亨德森集团 (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PCVX 的基金
- Jupiter Topco LLC 17.97M 股 · $1.04B · Q2 2026
- 骏利亨德森集团 16.58M 股 · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M 股 · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M 股 · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M 股 · $249.96M · Q2 2026
- Kynam Capital Management, LP 2.92M 股 · $169.88M · Q2 2026
- Caligan Partners LP 2.19M 股 · $127.23M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M 股 · $123.69M · Q2 2026
- Maverick 资本 1.61M 股 · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M 股 · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M 股 · $82.86M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M 股 · $80.23M · Q2 2026
更多关于 Bellevue Group AG
常见问题
How long has Bellevue Group AG held PCVX?
Bellevue Group AG has disclosed PCVX holdings in 9 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in PCVX?
As of Q2 2026, Bellevue Group AG holds 1.97M shares of PCVX (VAXCYTE INC), valued at $114.63M, representing 2.41% of its reported portfolio and ranking #12.
Has Bellevue Group AG been buying or selling PCVX?
In the latest 13F filing (Q2 2026), Bellevue Group AG increased its position in PCVX. The position peaked in Q2 2026 at 1.97M shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, 骏利亨德森集团, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.